A recent report by the FAIRR (Farm Animal Investment Risk & Return) Initiative, an investor network with 250 investor members representing $40 trillion assets under management, recognized Israeli biopharma company Mileutis for taking the lead in combating anti-microbial resistance (AMR).
Follow Israel Hayom on Facebook and Twitter
Antimicrobial resistance (AMR) is one of the top 10 global public health threats facing humanity, according to the World Health Organization. A leading cause of AMR is the overuse of antibiotics. The more we use antibiotics, the more chances bacteria will become resistant to them. This means that antibiotics will not work as well when we need them in the future.
The Director-General of the World Health Organization and the European Commissioner for Health and Food Safety, recently warned that: "So far 3.4 million lives have been lost to COVID-19, but the death toll from AMR could be higher unless there is urgent action."
The FAIRR report chose to profile Mileutis as a company which brings an alternative to the widespread use of antibiotics in the animal health sector. The report stated that Mileutis is "taking the lead in combating AMR," and noted that "in addition to addressing the global challenge of AMR, Mileutis' products have many benefits for the farmers, consumers, the environment, and the dairy cows themselves."
Mileutis co-founder and chief scientist Dr. Jose Iscovich said, "It is an honor for Mileutis to be featured by a top investment network such as FAIRR as one of the leading companies in the animal healthcare sector, working to reduce the risk of AMR with our revolutionary technology and products."
